west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "含血心脏停搏液" 2 results
  • 腺苷含血心脏停搏液在心瓣膜置换术中对心肌的保护作用

    摘要: 目的 研究含血心脏停搏液中加入外源性腺苷在心瓣膜置换术中对心肌的保护作用。 方法 将32例行心瓣膜置换术患者随机分为两组,腺苷组在含血心脏停搏液中加入外源性腺苷,对照组单用含血心脏停搏液,分别经主动脉根部或切开主动脉经冠状动脉窦直接灌注。于术前、主动脉开放后6 h、24 h、72 h采集患者桡动脉血,监测心肌肌酸激酶同工酶(CKMB)、肌钙蛋白I(cTnI);观察心脏停搏情况,术后机械辅助通气时间及术后正性肌力药物的应用情况;透射电子显微镜观察心肌超微结构的改变。 结果 两组患者均无死亡。腺苷组诱导心脏停搏时间较对照组短(P=0.021);腺苷组的CK-MB水平在主动脉开放后6 h、24 h,cTnI水平在主动脉开放后6 h、24 h、72 h均较对照组低(Plt;0.05);两组机械辅助通气时间和术后多巴胺使用剂量差异无统计学意义(Pgt;0.05);腺苷组心肌超微结构心肌损伤较对照组明显减轻。 结论 外源性腺苷加入心脏停搏液中能显著提高对心肌的保护效果。

    Release date:2016-08-30 06:01 Export PDF Favorites Scan
  • HTK versus Blood Cardioplegia for Myocardial Protection in Patients with Complex Coronary Artery Disease and Left Ventricular Dysfunction: A Case Control Study

    ObjectiveTo retrospectively compare and analyze the effect of myocardial protection between histidinetryptophane-ketoglutarate (HTK) and 4:1 blood cardioplegia in patients with complex coronary artery disease and left ventricular dysfunction. MethodsFrom January 2003 to July 2013, 2132 patients underwent isolated coronary artery bypass grafting (CABG) in our institution. Among them, 227 patients with complex coronary artery disease (left main or triple vessel disease) and left ventricular dysfunction (ejection fraction ≤ 50%) were included in this study. According to the category of cardioplegia utilized in the operations, the patients were divided into two groups: a HTK group (85 males and 4 females, n=89) and a blood cardioplegia group (113 males and 25 females, n=138). The average age was 62.78±9.30 years in the HTK group and 62.74±9.07 years in the blood cardioplegia group. The effect of myocardial protection between two groups was compared. ResultsAccording to the pre-operational data of these two groups, there was no significant difference identified in terms of basic characteristics and risk factors, even though more female patients were found in the blood cardiophegia group and more patients with renal dysfunction were found in the HTK group. In addition, the patients in the HTK group had more distal anastomosis, longer cardiopulmonary time and cross clamping time than those in the blood cardiophegia group. Based on the results measured by those primary assessment criteria,there was no significant difference being found between these two groups. However, on those secondary assessment criteria the pulmonary pressure and inotropic support after reperfusion were significantly higher in the HTK group than its counterpart. ConclusionFor patients with complex coronary artery disease and left ventricular dysfunction, HTK solution and blood cardioplegia provide similar effective myocardial protection. HTK doesn't significantly increase postoperative adverse cardiovascular events under the circumstance of longer ischemic time.

    Release date:2016-10-19 09:15 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content